A Pseudomonas putida strain engineered through synthetic biology capable of producing 5-carboxymethylpyridine-2-carboxylic acid (2,5-CPDCA) from lignin-derived monomers. 2,5-CPDCA is an analog of homoterephthalic acid, used for synthesizing plastic polyesters.
New bacterial polysaccharide with the ability to form reversible thermo-adaptive hydrogels. Its thermo-responsive properties make this polymer an effective tool for the development of innovative solutions in medicine, food, biotechnology and other fields.
A protein domain has been identified with the ability to direct membrane proteins and polypeptides of interest to the zymogen granules of pancreatic cells.
Technology based on a novel fungal enzymatic activity expressed in a tunable system, designed for the controlled production of hyaluronic acid oligosaccharides with defined structures and bioactive functionality.
Method that enables the rapid and homogeneous formation of three-dimensional cell spheroids, facilitating their production through automated systems for biomedical research and pharmaceutical development.
New marine-origin Cas9 nucleases for genetic editing using the CRISPR-Cas system, with applications ranging from gene therapy to the improvement of plant and animal organisms.
Stratum corneum lipid-matrix like liposomes capable of acting as oral mucosa impermeabilization agents to prevent the penetration of viruses or biocides through the mucosa.
New bacterial strain with a high capacity to capture CO2 and transform it into added-value nanocellulose. In addition, it produces nanocellulose from different types of agro-industrial waste, including crude glycerin residue from biodiesel production, sugar molasses, whey, etc...
This device provides a suitable method for the capture, detection and identification of whole airborne biological particles, including viruses (such as SARS-CoV-2) and other pathogens.
Isolation from the intestine of a healthy woman a novel bacteria strain that produces urolithins and development of a novel gut bacterial consortia comprising the mentioned novel bacterium and other bacteria wherein the consortia produce the mix of urolithins of metabotypes A or B, respectively, either in vitro or in vivo, including the newly characterized urolithin G.